Europe Non-Small Cell Lung Cancer Diagnostics Market, By Cancer Type (Lung Adenocarcinoma (LUAD), Lung Squamous Cell Carcinoma (LUSC), Large Cell Carcinoma And Others), Product (Reagents And Kits, Instruments, And Services And Software’s) Test(Imaging Test, Molecular Test, Biopsy, Sputum Cytology, Thoracentesis, Immunohistochemistry, And Others), End-User (Hospital, Clinical Laboratories, Academics And Others) Country (France, Russia, Netherlands, U.K., Germany, Italy, Spain, Turkey, Belgium, Switzerland and Rest of Europe) Industry Trends and Forecast to 2028.
Market Analysis and Insights: Europe Non-Small Cell Lung Cancer Diagnostics Market
Europe non-small cell lung cancer diagnostics market is expected to reach USD 846.60 million by 2028 from USD 331.31 million in 2020, growing at a steady CAGR of 12.5% in the forecast period of 2021 to 2028.
Non-small cell lung cancer is a disease in which malignant cells or cancer cells are formed in the tissues of the lungs. These are of different types, and each type has different cancer cells that grow and spread in different ways. The non-small cell lung cancer (NSCLC) types are squamous cell carcinoma, large cell carcinoma, and adenocarcinoma. In squamous cell carcinoma, the cancer forms in the thin, flat cells lining inside the lungs and is called epidermoid carcinoma. Large cell carcinoma cancer begins in several types of large cells. The adenocarcinoma type of cancer begins in the cells that line the alveoli and make substances such as mucus. One of the significant risks for non-small cell lung cancer (NSCLC) is that smoking and symptoms include a cough that doesn't go away and shortness of breath. Various tests are used, such as imaging tests, molecular tests, biopsies, and others, to diagnose and examine the cancer stage. Diagnosis is essential to identify the disease in time so that proper treatment could be given to patients.
The factors driving the growth of the non-small cell lung cancer diagnostics market are the usage of artificial intelligence and machine learning to improve the diagnostics procedures coupled with the rise in the number of geriatric population that is more susceptible to non-small cell lung cancer while high competition in the market and disturbed supply chain due to the COVID-19 pandemic may challenge the non-small cell lung cancer diagnostics market growth.
Furthermore, the rise in healthcare expenditure in developing countries and the increase in the adoption of new technology to diagnose non-small cell lung cancer will create huge opportunities for the global non-small cell lung cancer diagnostics market. On the other hand, the high competition in the market and disturbed supply chain due to the COVID-19 pandemic are expected to challenge the global non-small cell lung cancer diagnostics market.
The non-small cell lung cancer diagnostics market report provides details of market share, new developments, and product pipeline analysis, the impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, product approvals, strategic decisions, product launches, geographic expansions, and technological innovations in the market. To understand the analysis and the non-small cell lung cancer diagnostics market scenario, contact Data Bridge Market Research for an Analyst Brief. Our team will help you create a revenue impact solution to achieve your desired goal.
Europe Non-Small Cell Lung Cancer Diagnostics Market Scope and Market Size
The Europe non-small cell lung cancer diagnostics market is segmented into four notable segments based on the cancer type, products, test, and end-user. The growth among segments helps you analyze niche pockets of growth and strategies to approach the market and determine your core application areas and the difference in your target markets.
- On the basis of cancer type, the Europe non-small cell lung cancer diagnostics market is segmented into lung adenocarcinoma (LUAD), lung squamous cell carcinoma (LUSC), large cell carcinoma, and others. In 2021, the lung adenocarcinoma (LUAD) segment is expected to dominate the non-small cell lung cancer diagnostics market due to the increase in the number of adenocarcinoma lung cancer cases all around the world.
- On the basis of products, the Europe non-small cell lung cancer diagnostics market is segmented into reagents and kits, instruments and services, and software. In 2021, the instrument is expected to dominate the non-small cell lung cancer diagnostics market due to the increasing need for lung cancer diagnostics instruments to diagnose the disease on time.
- On the basis of the test, the Europe non-small cell lung cancer diagnostics market is segmented into imaging tests, molecular tests, biopsy, sputum cytology, thoracentesis, immunohistochemistry, and others. In 2021, the molecular test segment is expected to dominate the non-small cell lung cancer diagnostics market due to the rising need for a molecular test to diagnose lung cancer disease properly and with high accuracy.
- On the basis of end-user, the Europe non-small cell lung cancer diagnostics market is segmented into hospitals, clinical laboratories, academics, and others. In 2021, the clinical laboratories segment is expected to dominate the non-small cell lung cancer diagnostics market due to the growing need for non-small cell lung cancer diagnostics in clinical laboratories.
Europe Non-Small Cell Lung Cancer Diagnostics Market: Country Level Analysis
Europe non-small cell lung cancer diagnostics market is segmented into four notable segments based on the cancer type, products, test, and end-user.
Countries covered in the Europe Non-small cell lung cancer diagnostics market report are France, Russia, Netherlands, U.K., Germany, Italy, Spain, Turkey, Belgium, Switzerland, and the rest of Europe.
The products segment in the France region is expected to grow with the highest CAGR in the forecast period of 2021 to 2028 because of the increase in demand for diagnosis instruments to diagnose non-small cell lung cancer patients. Germany is expected to dominate the Europe non-small cell lung cancer diagnostics market with the highest market share owing to increased healthcare expenditure. Italy is expected to lead the growth of the Europe non-small cell lung cancer diagnostics market for products segment is dominating in this country due to rising healthcare expenditure.
The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impact the current and future trends of the market. Data points such as new sales, replacement sales, country demographics, regulatory acts, and import-export tariffs are some of the major pointers used to forecast the market scenario for individual countries. Also, the presence and availability of European brands and their challenges faced due to large or scarce competition from local and domestic brands, the impact of sales channels are considered while providing forecast analysis of the country data.
Growing Strategic Activities By Major Market Players To Enhance The Awareness For Non-Small Cell Lung Cancer Diagnostics, Is Boosting The Market Growth Of Non-Small Cell Lung Cancer Diagnostics Market.
The non-small cell lung cancer diagnostics market also provides you with a detailed market analysis for every country's growth in a particular market. Additionally, it provides detailed information regarding the market players' strategy and their geographical presence. The data is available for the historical period 2010 to 2019.
Competitive Landscape And Europe Non-Small Cell Lung Cancer Diagnostics Market Share Analysis
Europe non-small cell lung cancer diagnostics market competitive landscape provides details by a competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, India presence, production sites and facilities, company strengths and weaknesses, product launch, product trials pipelines, product approvals, patents, product width and breadth, application dominance, and technology lifeline curve. The above data points provided are only related to the companies' focus related to the non-small cell lung cancer diagnostics market.
Some of the major players operating in the non-small cell lung cancer diagnostics market are Abbott Laboratories, F. Hoffmann-La Roche Ltd, Agilent Technologies, Inc., QIAGEN, Quest Diagnostics Incorporated, NeoGenomics Laboratories, Inc., NanoString, Janssen Pharmaceutical NV, Inivata Ltd, bioMérieux SA, OncoCyte Corporation Inc., GENERAL ELECTRIC COMPANY, Eckert & Ziegler, Dr. Lal PathLabs, RIVERAIN TECHNOLOGIES, Oncimmune, among other domestic players. DBMR analysts understand competitive strengths and provide competitive analysis for each competitor separately.
Many contracts, agreements, and launches are also initiated by the companies worldwide, which are also accelerating the non-small cell lung cancer diagnostics market.
For instance,
- In March 2021, Agilent Technologies, Inc. acquired Resolution Bioscience for USD 550 million to strengthen its business in next-generation sequencing (NGS)-based oncology solutions
- In May 2021, QIAGEN launched FDA approved therascreen KRAS RGQ PCR Kit, which aids in the identification of non-small cell lung cancer (NSCLC) in patients
- In June 2020, F. Hoffmann-La Roche Ltd launched an automated digital pathology algorithm, uPath PD-L1 (SP263) image analysis, to diagnose non-small cell lung cancer (NSCLC) and improve the speed and accuracy of diagnosis treatment
Collaboration, product launch, business expansion, award and recognition, joint ventures, and other strategies by the market player are enhancing the company's footprints in the non-small cell lung cancer diagnostics market, which also provides the benefit for the organization's profit growth.
SKU-